Navigation Links
Glycosan BioSystems Seeks CE Mark in the European Union for HyStem-Rx, a Unique, Implantable Scaffold for Tissue Engineering
Date:6/1/2010

SALT LAKE CITY, June 1 /PRNewswire/ -- Glycosan BioSystems announced today that the Company has begun the process for gaining regulatory approval within the European Union for the use of HyStem-Rx as a resorbable scaffold for implanting autologous adipose derived cells in reconstruction and aesthetic plastic surgery procedures.  Upon approval, HyStem-Rx will receive a CE Mark as an implantable medical device.  HyStem-Rx will be indicated for use to correct subcutaneous contour defects arising from traumatic injury, oncologic resections, and other conditions that result in the loss of adipose tissue.

Spokesman for the Company said, "There is increasing recognition that development of successful cell-based therapies will require implanting cells within a matrix to protect them from natural inflammatory processes and to provide a three dimensional scaffold on which cells can attach and proliferate.  HyStem-Rx is a unique biomaterial that was designed as a biocompatible, resorbable mimic of the extra-cellular matrix to be used as a delivery matrix in cell-based therapies.   Pre-clinical studies have shown HyStem-Rx to support the growth of a wide variety of cell types and the proliferation and differentiation of embryonic stem cells as well as neural, hepatic, and adipose derived progenitor cells."

Glycosan BioSystems, Inc. is a privately held Salt Lake City biotechnology company that develops, manufactures, and sells unique biocompatible hydrogels that mimic the extracellular matrix, the complex mixture of macromolecules that holds cells together in tissues and organs.  The Company's products are used in cell culture and stem cell research and have applications as implantable, resorbable scaffolds for tissue engineering, regenerative medicine, and cell-based therapies.  Glycosan is the licensee of the University of Utah Research Foundation for certain intellectual property based on unique chemical cross-linking strategy to prepare hyaluronan based hydrogels from chemically modified hyaluronan and other extracellular matrix constituents.  More information on the Company and its products can be found at www.glycosan.com.


'/>"/>
SOURCE Glycosan BioSystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Online Tutorials for NCBI resources BioSystems and DCODE
2. Microbix Biosystems Re-files Annual Results With OSC
3. Microbix Biosystems Provides a Corporate Update
4. Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
5. Penguin Computing Forms OEM Agreement with Applied Biosystems for Scyld ClusterWare
6. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
7. Prosolia and Indigo BioSystems Come Together to Create FireFly(TM) Data Conversion Software for Mass Spectrometers
8. Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research
9. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
10. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
11. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):